Advertisement

Effect of interferons and an interferon inducer on malignant brain tumors

  • Kintomo Takakura
  • Osamu Nakamura
  • Masakatsu Nagai
  • Kazuhiro Nomura
  • Heitaro Mogami

Abstract

Three case reports of long-term administration of human fibroblast interferon-β (Hu IFN-β) and interferon inducer poly ICLC on malignant glioma patients were presented. Regression of the tumor was demonstrated in a case of anaplastic astrocytoma by intravenous administration of Hu IFN-β for more than two and half years. The suppressive effect of intratumoral administration in a glioblastoma patient was also presented. The effects of Hu IFN-β and recombinant IFN-α on glioblastoma multiforme, anaplastic astrocytoma and other gliomas were summarized. The suppressive effect and complications of intravenous administration of poly ICLC on malignant glioma were presented and discussed.

Keywords

interferon interferon inducer poly ICLC glioma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mahaley Jr MS, Urso MB, Whaley RA, Williams TE, Guaspari A: Interferon as adjuvnat therapy with initial radiotherapy of patients with anaplastic gliomas. J Neurosurg 61: 1069–1971, 1984PubMedCrossRefGoogle Scholar
  2. 2.
    Nagai M: Clinical trials of human fibrolast interferon (Hu IFN-β) on malignant brain tumors. J Jpn Soc Cancer Ther 18: 60–68, 1983Google Scholar
  3. 3.
    Nagai M, Arai T, Kohno S, Iizuka E: Current status of interferon therapy on malignant brain tumor. Gan No Rinsho 29: 608–615, 1983 (Jpn)PubMedGoogle Scholar
  4. 4.
    Boëthius J, Blomgren H, Collins VP, Greitz T, Strander H: The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme. Acta Neurochir 68: 239–251, 1983CrossRefGoogle Scholar
  5. 5.
    Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T: Effect of human leukocyte interferon on malignant brain tumors. Cancer 51: 1976–1981, 1983PubMedCrossRefGoogle Scholar
  6. 6.
    Ueda S, Hirakawa K, Suzuki K, Nakagawa Y, Imura N, Kishida T: Interferon therapy for brain tumor patients. No Shinkei Geka 10: 149–154, 1982 (Jpn)PubMedGoogle Scholar
  7. 7.
    Nakamura O, Takakura K, Kobayashi S: Effect of human interferon-β in the treatment of malignant brain tumors. UCLA Symp Molecular Cell Biol 24: 465–477, 1982Google Scholar
  8. 8.
    Nakamura O, Takakura K: Therapeutic effect of Hu-Interferon-β and interferon inducer (poly ICLC) in the malignant brain tumor. Tokyo J Med Sci 89: 137–146, 1982Google Scholar
  9. 9.
    Nakamura O, Shitara J, Matsutani M, Takakura K, Machida H: Phase I-II trials of poly (ICLC) in malignant brain tumor patients. J Interferon Res 2: 1–4, 1982PubMedCrossRefGoogle Scholar
  10. 10.
    Nakamura O, Shitara N, Matsutani M, Takakura K, Machida H: Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor. Brain and Nerve 34: 267–273, 1982PubMedGoogle Scholar
  11. 11.
    Machida H, Takezawa J, Kuninaka A, Yoshino H, Nakamura O, Takakura K: Interferon induction and therapy of brain tumors in rats by poly (ICLC). Microbiol Immunol 26: 353–358, 1982PubMedGoogle Scholar
  12. 12.
    Committee of Brain Tumor Registry in Japan: Brain Tumor Registry in Japan, pp 57–65, 1984Google Scholar
  13. 13.
    Cutler S: Computation of survival rate. NCI Monograph 15: 381–385, 1964Google Scholar
  14. 14.
    Taguchi T, Takakura K, Kimura K, Ohta K, Izumo M, Koyama Y, Niizima T, Ikeda S, Akaboshi Y: Clinical studies of recombinant leukocyte α-interferon (r-IFN-αA, Ro 22-8181). Kishida T (ed). Proc Intern Symp on Interferons, pp 173–180, 1983Google Scholar
  15. 15.
    Kimura K: Overview of phase II study of human lymphoblastoid interferon (HLBI) for solid tumor and blood cancer in Japan. Kishida T (ed). Proc Intern Sym on Interferons, pp 157–162, 1983Google Scholar
  16. 16.
    Feun L, Gutterman J, Quesada J, Stewart D, Leavens J, Burgess J, Benjamin R: Phase I study of interferon admin-istered via in dwelling Ommaya reservoir for the treatment of progressive malignant gliomas. Proc 13th Intern Cancer Cong, Seattle, Sept 8-15, No 93, p 172, 1982Google Scholar

Copyright information

© Martinas Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • Kintomo Takakura
    • 1
  • Osamu Nakamura
  • Masakatsu Nagai
    • 2
  • Kazuhiro Nomura
    • 3
  • Heitaro Mogami
    • 4
  1. 1.Dept. of NeurosurgeryUniv. of TokyoJapan
  2. 2.Dept. of NeurosurgeryUniv. of DokkyoJapan
  3. 3.Dept. of NeurosurgeryNational Cancer CenterJapan
  4. 4.Dept. of NeurosurgeryUniv. of OsakaJapan

Personalised recommendations